TY - JOUR T1 - Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection JF - Aliment. Pharmacol. Ther Y1 - 2015 A1 - Z M Younossi A1 - Park, H. A1 - Saab, S. A1 - Ahmed, A. A1 - D. Dieterich A1 - Gordon, S.C. KW - administration & dosage KW - Adult KW - analogs & derivatives KW - Antiviral Agents KW - Benzimidazoles KW - Comparative Study KW - complications KW - Cost-Benefit Analysis KW - Disease KW - drug therapy KW - Drug Therapy,Combination KW - economics KW - Fibrosis KW - Fluorenes KW - genetics KW - Genotype KW - genotype 1 KW - HCV KW - Health KW - Health Care Costs KW - Hepacivirus KW - hepatitis KW - Hepatitis C KW - hepatitis C virus KW - Hepatitis C,Chronic KW - Humans KW - Incidence KW - Infection KW - interferon KW - Interferons KW - isolation & purification KW - Liver KW - Liver Cirrhosis KW - Liver Diseases KW - Male KW - Medicine KW - methods KW - Middle Aged KW - Patients KW - pegylated KW - pegylated interferon KW - protease inhibitor KW - Quality-Adjusted Life Years KW - Research KW - Research Support KW - Ribavirin KW - sofosbuvir KW - sustained virologic response KW - SVR KW - therapeutic use KW - therapy KW - treatment KW - Treatment Outcome KW - treatment-naive KW - Uridine KW - Uridine Monophosphate KW - virology VL - 41 SP - 544-563 IS - 6 ER -